Pier 88 Investment Partners LLC Fate Therapeutics Inc Transaction History

Pier 88 Investment Partners LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$29.67 - $60.28 $322,957 - $656,147	-10,885 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $421,948 - $567,478	8,820 Added 427.12%	10,885 $637,000
Q3 2021 Nov 12, 2021	SELL	$59.27 - $95.73 $457,979 - $739,705	-7,727 Reduced 78.91%	2,065 $122,000
Q2 2021 Aug 13, 2021	BUY	$67.25 - $92.52 $201,750 - $277,560	3,000 Added 44.17%	9,792 $850,000
Q1 2021 May 14, 2021	SELL	$72.16 - $117.4 $40,409 - $65,744	-560 Reduced 7.62%	6,792 $560,000
Q4 2020 Feb 12, 2021	SELL	$38.09 - $100.95 $912,826 - $2.42 Million	-23,965 Reduced 76.52%	7,352 $1.85 Million
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $219,712 - $292,612	7,225 Added 29.99%	31,317 $1.25 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $486,899 - $848,761	24,092 New	24,092 $827,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Pier 88 Investment Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Pier 88 Investment Partners LLC with notifications on news.